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Purpose. To determine tolerability and efﬁcacy of induction chemotherapy (I-CHT) followed by simultaneous integrated
boost intensity-modulated radiotherapy (SIB-IMRT) with concurrent chemotherapy/cetuximab (C-CHT) for locally-advanced
squamous-head-and-neck carcinoma (LA-SHNC).
Methods and materials. Nineteen patients (13M/6F) with LA-SHNC (stage III:3–IV:16) were enrolled in a prospective study between
March’07 and September’10, including 6 oral cavity/5 oropharynx/5 hypopharynx/2 larynx/1 paranasal sinuses. Four P16-HPV
were identiﬁed. Two-cycles of Docetaxel/CDDP/Capecitabine, followed by SIB-IMRTandweekly CDDP/Cetuximabwere prescribed.
Staging studies included PET-CT with thermoplastic mask, used for to delimited target volumes. Weekly Cone-beam-IGRT was
used. The prescribed SIB-IMRT doses to GTV, CTV and PTV were 73.6Gy (2.24Gy/f), 56.2Gy (1.7Gy/f) and 51.2Gy (1.6Gy/f), respec-
tively, in 30 daily fractions. Survival, patterns of failure and acute/late toxicity were analyzed. Local recurrences were identiﬁed
on MRI and/or PET/CT, and contoured (V-recur) on the original planning-CT. Local failure was classiﬁed according to the location
of V-recur respect the 95% isodose line GTV prescription (IDL) as “in-ﬁeld”, “marginal” and “outside” when >95%, 20–95% or <20%
of V-recur was within the 95% IDL, respectively. Data from DVH of target and organs-at-risk volume were analyzed.
Results. Eighteen patients received 2-cycles of I-CHT. All patients received the prescribed SIB-IMRT dose, median of C-CHT 6-
cycles. After complete treatments, objective response was 95% (79%complete/16%partial). Highest toxicity during I-CHT was
grade3–4 (31%). During SIB-IMRT, most frequent grade >3 toxicity was mucositis/dysphagia (32%). No treatment-related dead was
observed. Two osteonecrosis were observed. None other late toxicity grade >2 was observed. After 37 months (18–56) median
follow-up, 6 patients (31%) relapsed: 1 distant and 5 local (4 “in ﬁed”/1 “marginal”). Three-year D-DFS, L-DFS, DFS, and OS were
94%, 69%, 54%, and 66%, respectively. Univariate study determinate worse OS in undifferentiated SHNC type (p=0.028), and no
complete response after treatments (p=0.001). Tumor location was predictor of local control: better in oropharyngeal and laryn-
geal (p=0.001). Multivariate analysis showed cervical esophagus V50>7% (p=0.001) as predictor of acute mucositis/dysphagia
≥grade3 (p=0.005).
Conclusion. SIB-IMRT with C-CHT after I-CHT is feasible and well tolerated schedule that shortens the overall treatment time in
radical treatment of LA-HNSC, achieving encouraging local and distant control rates. A larger population of patients is needed.
http://dx.doi.org/10.1016/j.rpor.2013.03.286
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Introduction. Skull base (SB) chondrosarcoma (CSA) is approximately 6% of skull base lesions. The therapeutic approach is con-
troversial. Multidisciplinary treatment using protontherapy after maximal surgery enables a local control(90–100%) at 5 years.
Objetive. A case of CSA that the treatment is with high technology.
Case report. A case of CSA in a 35-year-old woman with 8 weeks of pregnancy presenting symtoms of sudden onset diplopia.
Magnetic resonance imaging (MRI) showed lytic lesion centered in the right foramen, with involvement of the boulder and
inferior walls of internal auditory canal, clivus, carotid canal, hole torn posterior cavernous sinus and extension infracraneal,
suggestive a right petroclival chondroma. Due to her pregnancy was decided to wait and induce labor at 37 weeks. Subsequently
the patient presented diplopia and right otalgia, likewise dysphagia and hypoesthesia in the left arm. Ten months after diagnosis,
the patientwasunderwent to a subtotal resection.Histologically, the tumorwas awell-differentiated chondrosarcoma. The tumor
cellswere immunoreactive for S100(+++) vimentin(+++), AE1/AE3:(−) CAM5.2:(−) EMA(−).The CT scan post-surgery showed tumor
persistence although the extension study was negative. The neuro-oncology group decided adyuvant proton radiotherapy.The
patient was translated to the Institut Curie Orsay, local radiation with tomotherapy was given 34.2Gy, boost with protontherapy
36Gy, TD:70.2Gy/1.8Gy.
Results. The MRI revealed no changed in residual tumor. The patient has a complete recovery of right VI cranial nerve palsy,
partially of the VII left pair and tinnitus. Regular follow-up the last 7 months.
